Rödl & Partner advises Grande Bio-tech Co. Ltd. in the investment of Jena-based oncgnostics GmbH

Stuttgart, 30 October 2023: Rödl & Partner advised Hong Kong-based Grande Bio-tech Co. Ltd. on a seven-digit Euro investment in the Jena-based diagnostic company oncgnostics GmbH. Grande Bio-tech Co. Ltd. is the lead investor of this financing round. Co-investors include bm-t (Beteiligungsmanagement Thüringen GmbH) and HTGF (High-Tech Gründerfonds).

oncgnostics’ GynTect test received the approval for the Chinese market in 2022. The new investment funds will further R&D activities and help oncgnostics expand its businesses.

Rödl & Partner’s venture capital team and its dedicated China Desk supported Grande Bio-tech Co. Ltd as legal advisor in this transaction. Partner Jiawei Wang, Head of China Desk, based in the Stuttgart office, was responsible for the overall project lead.

About oncgnostics GmbH

oncgnostics GmbH is a biotech startup spin off from the Jena University Hospital, engaging in research and development of molecular biology tests for cancer diagnostics based on epigenetic changes in the human genome. With the product GynTect, oncgnostics introduced an innovation in the field of cervical cancer screening. Currently, oncgnostics is developing further tests for head and neck cancers.

Advisors to Grande Bio-tech Co. Ltd.

Rödl & Partner

Jiawei Wang LL.M., Partner (China Outbound Investment), Stuttgart, Project Lead – Legal

Alexander von Chrzanowski (Employment Law, IP), Associate Partner, Jena – Legal

Qinglu Shao, Senior Associate (China Outbound Investment), Stuttgart – Legal

Moritz Sippel, Senior Associate (Merger & Acquisition), Munich – Legal

Lara Kiefer, Senior Associate (Merger & Acquisition), Munich – Legal

Contact

Contact Person Picture

Jiawei Wang, LL.M.

Partner

+49 711 7819 144 32

Send inquiry